![]() |
市場調查報告書
商品編碼
1630515
全球近距離放射治療市場:以產品類型(高劑量率與低劑量率)、技術、適應症、最終用戶和地區預測 2032 年Brachytherapy Market Research Report Information, By Product, By Type (High Dose-Rate Brachytherapy, Low Dose-Rate Brachytherapy), By Technique, By Indication, By End-Users And By Region Industry Forecast Till 2032 |
全球近距離放射治療市場規模預計將從2023 年的9.8 億美元成長到2024 年的10.7 億美元,預測期內的複合年增長率為6.84%,到2032 年將達到10.7 億美元。到2032 年將成長至 2020 年將達到 19.4 億美元。
近距離放射治療的引入顯著加速了近距離放射治療市場的成長,因為它為癌症患者提供了更多的治療選擇。隨著越來越多的患者尋求比傳統放射療法更有效的替代療法,醫療機構正在擴大其服務範圍,包括這種有針對性的微創技術。近距離放射治療將目標劑量的放射線直接傳送到惡性腫瘤,同時保護健康組織,進而改善患者的治療效果和滿意度。
此外,更短的治療時間和更少的副作用已得到患者和醫療保健提供者的更多接受。 2024 年 9 月,印度卡納塔克邦醫學院和研究所引入了近距離放射治療,這是子宮頸癌和食道癌治療的重大進展。
區域展望
2023 年,北美將佔據最大的市場佔有率。此外,預計亞太地區在預測期內將呈現最高成長,複合年增長率為 7.98%。
北美市場的成長代表著癌症治療策略的重大突破。隨著局部癌症,尤其是子宮頸癌、乳癌和攝護腺癌的增加,對有效治療的需求日益增長。
受多種因素影響,亞太市場正快速擴張。癌症,尤其是乳癌、攝護腺癌和子宮頸癌發生率的顯著上升,促使對有效替代治療方法的需求增加。
本報告研究了全球近距離放射治療市場,提供了市場定義和概述、影響市場成長的各種因素的分析、市場規模的趨勢和預測,以及各個細分市場、地區/區域的市場信息。
Brachytherapy Market Research Report Information, By Product (Afterloaders & Applicators, Radioactive Seeds, Electronic Brachytherapy, Imaging Systems, and Others), By Type (High Dose-Rate (HDR) Brachytherapy, Low Dose-Rate (LDR) Brachytherapy), By Technique (Interstitial Brachytherapy, Intracavitary Brachytherapy), By Indication (Prostate Cancer, Breast Cancer, Cervical Cancer, Skin Cancer, and Others), By End-Users (Hospitals & Specialty Clinics, Cancer Treatment Centers, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) Industry Forecast Till 2032
In 2023, the brachytherapy market was estimated to be worth USD 0.98 billion. With a compound annual growth rate (CAGR) of 6.84% from 2024 to 2032, the sector is expected to increase from USD 1.07 billion in 2024 to USD 1.94 billion by 2032. The global rise in cancer cases and the number of new product launches are fueling the market's expansion.
By giving cancer patients more treatment alternatives, the introduction of brachytherapy services is greatly accelerating the growth of the brachytherapy market. More patients looking for efficient substitutes for conventional radiation therapy are drawn to healthcare facilities as they broaden their offers to include this focused, minimally invasive technique. Brachytherapy is improving patient outcomes and satisfaction by directly delivering focused radiation doses to malignancies while protecting healthy tissue.
Furthermore, patients' and healthcare providers' acceptance is being aided by shorter treatment durations and fewer adverse effects. An important development in the treatment of cervical and esophageal cancers was the introduction of brachytherapy services by Karnataka Medical College and Research Institute (India) in September 2024.
Perspectives on Market Segments
Afterloaders & Applicators, Radioactive Seeds, Electronic Brachytherapy, Imaging Systems, and Others are the product-based divisions of the Brachytherapy market.
The market has been divided into two segments based on type: low dose-rate (LDR) brachytherapy and high dose-rate (HDR) brachytherapy.
The brachytherapy market has been divided into two segments based on technique: intracavity brachytherapy and interstitial brachytherapy.
The market has been divided into several segments based on indications, including skin cancer, breast cancer, prostate cancer, and cervical cancer.
The market for brachytherapy has been divided into three segments based on end users: cancer treatment centers, hospitals and specialty clinics, and others.
Regional Perspectives
The market for brachytherapy has been divided into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. In 2023, North America held the biggest market share. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the highest CAGR of 7.98%.
The market for brachytherapy is expanding quickly in North America, which is indicative of major developments in cancer treatment strategies. The need for efficient treatments has increased as cancer rates grow, especially for localized types including cervical, breast, and prostate cancers.
The market for brachytherapy in Asia-Pacific is expanding rapidly due to a number of interconnected factors. The need for efficient treatment alternatives has increased due to a notable rise in the incidence of cancer, especially breast, prostate, and cervical malignancies.
In addition, the rest of the world is further separated into South America, Africa, and the Middle East. The region's economic growth has raised healthcare expenditures, improving access to cutting-edge cancer treatment alternatives.
Siemens Healthineers AG, Elekta, BEBIG Medical Gmbh, Becton, Dickinson and Company (US), GE Healthcare (US), Merit Medical Systems (US), Best Medical International, Inc. (US), IsoAid, LLC (US), Theragenics Corporation, Eckert & Ziegler, and others are major competitors in the brachytherapy market.